The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists.
The wisdom’s changed (or some of it, anyway). Granted, IPOs worldwide in biopharma are still playing second fiddle to M&A,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?